Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies

J Hepatol. 2022 Feb;76(2):343-352. doi: 10.1016/j.jhep.2021.09.034. Epub 2021 Oct 6.

Abstract

Background & aims: Microvascular invasion (MVI), a major risk factor for tumor recurrence after surgery in hepatocellular carcinoma (HCC), is only detectable by microscopic examination of the surgical specimen. We aimed to define a transcriptomic signature associated with MVI in HCC than can be applied to formalin-fixed paraffin-embedded (FFPE) biopsies for use in clinical practice.

Methods: To identify a gene expression signature related to MVI by using NanoString technology, we selected a set of 200 genes according to the literature and RNA-sequencing data obtained from a cohort of 150 frozen HCC samples previously published. We used 178 FFPE-archived HCC samples, including 109 surgical samples for the training set and 69 paired pre-operative biopsies for the validation set. In 14 cases of the training set, a paired biopsy was available and was also analyzed.

Results: We identified a 6-gene signature (ROS1, UGT2B7, FAS, ANGPTL7, GMNN, MKI67) strongly associated with MVI in the training set of FFPE surgical HCC samples, with 82% accuracy (sensitivity 82%, specificity 81%, AUC 0.82). The NanoString gene expression was highly correlated in 14 paired surgical/biopsy HCC samples (mean R: 0.97). In the validation set of 69 FFPE HCC biopsies, the 6-gene NanoString signature predicted MVI with 74% accuracy (sensitivity 73%, specificity 76%, AUC 0.74). Moreover, on multivariate analysis, the MVI signature was associated with overall survival in both sets (hazard ratio 2.29; 95% CI 1.03-5.07; p = 0.041).

Conclusion: We defined a 6-gene signature that can accurately predict MVI in FFPE HCC biopsy samples, which is also associated with overall survival, although its survival impact must be confirmed by extensive study with further clinical data.

Lay summary: Microvascular invasion, a major risk factor for tumor recurrence after surgery in hepatocellular carcinoma, is only detectable by microscopic examination of a surgical specimen. In this study, we defined a relevant surrogate signature of microvascular invasion in hepatocellular carcinoma that may be applied in clinical practice with routine tumor biopsy and integrated into the therapeutic strategy.

Keywords: Hepatocellular carcinoma; NanoString technology; biopsy; formol fixation; microvascular invasion; prognosis; signature.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Angiopoietin-Like Protein 7 / analysis
  • Angiopoietin-Like Protein 7 / blood
  • Angiopoietin-like Proteins / analysis
  • Angiopoietin-like Proteins / blood
  • Biomarkers / analysis
  • Biomarkers / blood
  • Biopsy / methods
  • Biopsy / statistics & numerical data*
  • Carcinoma, Hepatocellular / blood*
  • Carcinoma, Hepatocellular / epidemiology
  • Carcinoma, Hepatocellular / pathology*
  • Cohort Studies
  • Female
  • France / epidemiology
  • Geminin / analysis
  • Geminin / blood
  • Gene Expression / genetics*
  • Gene Expression / physiology
  • Glucuronosyltransferase / analysis
  • Glucuronosyltransferase / blood
  • Humans
  • Ki-67 Antigen / analysis
  • Ki-67 Antigen / blood
  • Liver Neoplasms / blood
  • Liver Neoplasms / epidemiology
  • Liver Neoplasms / pathology
  • Male
  • Microvessels / physiopathology
  • Middle Aged
  • Protein-Tyrosine Kinases / analysis
  • Protein-Tyrosine Kinases / blood
  • Proto-Oncogene Proteins / analysis
  • Proto-Oncogene Proteins / blood
  • fas Receptor / analysis
  • fas Receptor / blood

Substances

  • ANGPTL7 protein, human
  • Angiopoietin-Like Protein 7
  • Angiopoietin-like Proteins
  • Biomarkers
  • FAS protein, human
  • GMNN protein, human
  • Geminin
  • Ki-67 Antigen
  • MKI67 protein, human
  • Proto-Oncogene Proteins
  • fas Receptor
  • UGT2B7 protein, human
  • Glucuronosyltransferase
  • Protein-Tyrosine Kinases
  • ROS1 protein, human